Table 5.
Multivariate analysis of HIV factors associated with prevalent composite-HSIL among HIV-positive men in the Study of the Prevention of Anal Cancer, overall and stratified by composite-AIN2 and composite-AIN3 diagnoses.
|
Composite-negative versus Composite-HSILa(n=152) |
Composite-negative versus Composite-AIN2b(n=69) |
Composite-negative versus Composite-AIN3c(n=131) |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Variable | n (%) | Adjusted OR (95% CI) | p-Value | n (%) | Adjusted OR (95% CI) | p-Value | n (%) | Adjusted OR (95% CI) | p-Value | |
| Nadir CD4+T-cell count | ≥500 | 12/20 (60.0) | 1.00 | 0.107 | 3/11 (27.3) | 1.00 | 0.592 | 9/17 (52.9) | 1.00 | 0.080 |
| 200–500 | 38/61 (62.3) | 1.10 (0.39–3.10) | 9/32 (28.3) | 1.04 (0.21–5.32) | 29/52 (55.8) | 1.12 (0.37–3.36) | ||||
| <200 | 51/68 (75.0) | 2.00 (0.70–5.71) | 9/26 (34.6) | 1.41 (0.30–6.67) | 42/59 (71.2) | 2.20 (0.72–6.64) | ||||
| Result of last CD4+T-cell count | >500 | 57/94 (60.6) | 1.00 | 0.181 | 10/47 (21.3) | 1.00 | 0.324 | 47/84 (56.0 | 1.00 | 0.248 |
| 500–351 | 29/35 (82.9) | 2.95 (1.02–8.52) | 8/14 (57.1) | 4.12 (1.05–16.01) | 21/27 (77.8) | 3.08 (0.98–9.69) | ||||
| ≤350 | 11/15 (73.3) | 1.70 (0.43–6.74) | 3/7 (42.9) | 2.68 (0.44–16.14) | 8/12 (66.7) | 1.05 (0.20–5.52) | ||||
| Result of last HIV viral load testd | Undetectable | 90/132 (68.2) | 1.00 | 0.669 | 17/59 (28.8) | 1.00 | 0.216 | 73/115 (63.5) | 1.00 | 0.695 |
| Detectable | 9/12 (75.0) | 1.40 (0.30–6.63) | 3/6 (50.0) | 3.21 (0.51–20.38) | 6/9 (66.7) | 0.70 (0.12–4.18) | ||||
| Currently on any ART | No | 5/7 (71.4) | 1.00 | 0.754 | 2/4 (50.0) | 1.00 | 0.373 | 3/5 (60.0) | 1.00 | 0.666 |
| Yes | 99/145 (68.3) | 0.74 (0.12–4.72) | 19/65 (29.2) | 0.37 (0.04–3.30) | 80/126 (63.5) | 1.56 (0.21–11.68) | ||||
| History of AIDS-defining illness | No | 66/102 (64.7) | 1.00 | 0.319 | 16/52 (30.8) | 1.00 | 0.768 | 50/86 (58.1) | 1.00 | 0.175 |
| Yes | 36/48 (75.0) | 1.55 (0.65–3.70) | 5/17 (29.4) | 0.82 (0.22–3.03) | 31/43 (72.1) | 1.89 (0.75–4.71) | ||||
a Comparing men with composite negative result (n=48) to men with HSIL detected on by either cytology or histology (n=104).
b Comparing men with composite negative result (n=48) to men with HSIL-AIN2 on cytology and/or AIN2 on histology without a diagnosis of AIN3 on either (n=21).
c Comparing men with composite negative result (n=48) to men with HSIL-AIN3 on cytology or histology (n=83). Adjusted for number of HR-HPV types and HPV16 detected on anal swab, age and smoking exposure.
d Undetectable viral load: <50 copies; Detectable viral load ≥50 copies.
Men in the composite-LSIL (n=155) and composite-ASC-H (n=55) were excluded from analyses of risk factors.